Theradiag is forecasting sales of 12.2 million euros for 2022, an increase of 9.7% in line with its business plan, with a greater proportion generated outside France (55% vs. 52% in 2021).

The company points out that its Theranostics business will again post solid growth in 2022 (+10.1%), despite fewer instruments sold, as will its historical in vitro diagnostics business (+9.2%), despite the closure of the Covid test business in 2021.

Driven by its new strategic plan, the company will continue to improve its performance indicators in the coming half-years", concludes Pierre Morgon, Chairman of Theradiag's Board of Directors.

Copyright (c) 2023 CercleFinance.com. All rights reserved.